S. Ostrow

527 total citations
19 papers, 427 citations indexed

About

S. Ostrow is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Ostrow has authored 19 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Ostrow's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (5 papers). S. Ostrow is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (5 papers). S. Ostrow collaborates with scholars based in United States and Malaysia. S. Ostrow's co-authors include Joseph Aisner, Peter H. Wiernik, P H Wiernik, Merrill J. Egorin, Dagmar Hahn, Robert D. Richards, N R Bachur, Davis M. Hahn, David A. Van Echo and P. H. Wiernik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

S. Ostrow

19 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Ostrow United States 13 235 138 105 61 56 19 427
Y. Kenis Belgium 12 238 1.0× 190 1.4× 65 0.6× 85 1.4× 109 1.9× 59 503
Franco Corbella Italy 11 145 0.6× 172 1.2× 172 1.6× 78 1.3× 50 0.9× 32 509
Seth Kaufman United States 12 103 0.4× 93 0.7× 181 1.7× 188 3.1× 67 1.2× 19 678
G Deppe United States 12 72 0.3× 74 0.5× 54 0.5× 176 2.9× 42 0.8× 27 387
Jørgen Kirkegaard Denmark 15 199 0.8× 138 1.0× 61 0.6× 241 4.0× 31 0.6× 25 700
James C. Wernz United States 9 370 1.6× 98 0.7× 147 1.4× 44 0.7× 59 1.1× 11 561
Nicolas Magné France 13 214 0.9× 236 1.7× 35 0.3× 105 1.7× 99 1.8× 60 657
F. G. Kamar Lebanon 9 154 0.7× 167 1.2× 35 0.3× 52 0.9× 41 0.7× 23 316
Sashidhar Yeluri United Kingdom 10 107 0.5× 61 0.4× 29 0.3× 142 2.3× 189 3.4× 24 534
D. Gilson United Kingdom 10 86 0.4× 87 0.6× 93 0.9× 12 0.2× 27 0.5× 21 292

Countries citing papers authored by S. Ostrow

Since Specialization
Citations

This map shows the geographic impact of S. Ostrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Ostrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Ostrow more than expected).

Fields of papers citing papers by S. Ostrow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Ostrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Ostrow. The network helps show where S. Ostrow may publish in the future.

Co-authorship network of co-authors of S. Ostrow

This figure shows the co-authorship network connecting the top 25 collaborators of S. Ostrow. A scholar is included among the top collaborators of S. Ostrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Ostrow. S. Ostrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
2.
Madajewicz, Stefan, Rafael C. Caruso, Michael Fried, et al.. (2000). Phase I Chemotherapy Study of Biochemical Modulation of Folinic Acid and Fluorouracil by Gemcitabine in Patients With Solid Tumor Malignancies. Journal of Clinical Oncology. 18(20). 3553–3557. 32 indexed citations
3.
Echo, David A. Van, Margaret Whitacre, Martin Helrich, et al.. (1984). Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer. 53(12). 2585–2591. 32 indexed citations
4.
Fuks, Joachim Z., Merrill J. Egorin, Joseph Aisner, et al.. (1983). Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology. 10(2). 104–108. 14 indexed citations
5.
Fuks, Joachim Z., Joseph Aisner, David A. Van Echo, et al.. (1983). Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.. Journal of Clinical Oncology. 1(5). 295–301. 22 indexed citations
6.
Ostrow, S.. (1983). The Management of Nonseminomatous Testicular Cancer: Current Therapy and Future Directions. The American Journal of the Medical Sciences. 285(1). 24–37. 3 indexed citations
7.
Fuks, Joachim Z., Joseph Aisner, Desmond N. Carney, et al.. (1982). A phase II trial of vindesine in patients with refractory small-cell carcinoma of the lung. American Journal of Clinical Oncology. 5(1). 49–52. 9 indexed citations
8.
Fuks, Joachim Z., Joseph Aisner, Desmond N. Carney, et al.. (1982). A phase II trial of vindesine in patients with refractory small-cell carcinoma of the lung. American Journal of Clinical Oncology. 5(1). 49–52. 1 indexed citations
9.
Ostrow, S., Charles H. Diggs, John C. Sutherland, & Peter H. Wiernik. (1981). Causes of death in patients with non-Hodgkin's lYMPHOMA. Cancer. 48(3). 779–782. 22 indexed citations
10.
Wiernik, P H, et al.. (1981). Nodular lymphoma. Prolongation of survival by complete remission.. PubMed. 4(2). 107–14. 9 indexed citations
11.
Aisner, Joseph, et al.. (1981). Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Medical and Pediatric Oncology. 9(1). 47–59. 21 indexed citations
12.
Ostrow, S., et al.. (1981). Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer.. PubMed. 65(3-4). 323–5. 26 indexed citations
13.
Ostrow, S., Merrill J. Egorin, Davis M. Hahn, et al.. (1981). High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.. PubMed. 65(1-2). 73–8. 66 indexed citations
14.
Ostrow, S., Merrill J. Egorin, Joseph Aisner, N R Bachur, & P. H. Wiernik. (1980). High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.. PubMed. 3(1). 23–7. 42 indexed citations
15.
Ostrow, S., Merrill J. Egorin, Davis M. Hahn, et al.. (1980). Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer. 46(8). 1715–1721. 28 indexed citations
16.
Wehling, Martin, et al.. (1980). Quantitative changes in cis-dichlorodiammineplatinum(II) speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results.. PubMed. 64(1). 123–32. 6 indexed citations
17.
Reinstein, L. E., S. Ostrow, & P H Wiernik. (1980). Peripheral neuropathy after cis-platinum (II) (DDP) therapy.. PubMed. 61(6). 280–2. 23 indexed citations
18.
Aisner, Joseph, et al.. (1979). Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 23(4). 292–9. 15 indexed citations
19.
Ostrow, S., Dagmar Hahn, P H Wiernik, & Robert D. Richards. (1978). Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(10). 1591–4. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026